Amsterdam UMC, location VUmc

amsterdamumc.org

Live pipeline data from ClinicalTrials.gov, refreshed daily.

Total trials

300

Active

67

Phase 3

18

Total enrollment

100,457

Pipeline matrix

Showing 22 of 22 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
ertugliflozine1
Ocrelizumab1
Sotatercept1
Macrogol Only Product in Oral Dose Form1
Magnesium hydroxide 724mg1
Pembrolizumab2
Rituximab1
Neoadjuvant systemic therapy1
Gemcitabine, Cisplatin1
Celecoxib 400mg1
repetitive transcranial magnetic stimulation1
Folfirinox1
Iberdomide plus low-dose cyclophosphamide and dexamethasone1
Metformin1
Group 1 - Intradermal ipilimumab1
Group 2 - Conventional treatment1
Inotropes1
FES1
Systematic multidisciplinary medication review + ACP1
[18F]F-AraG PET imaging1
[89Zr]Zr-Df-Crefmirlimab PET imaging1
Intrathecal Baclofen Pump1

Next readouts

  • 2025-12
  • 2025-12
  • 2025-12-01
  • 2026-05-01
  • 2026-07
  • 2026-12
  • 2026-12
  • 2027-02
  • 2027-05
  • 2027-05-01

Top conditions

  • Multiple Sclerosis11
  • Coronary Artery Disease7
  • Breast Cancer7
  • Type 2 Diabetes6
  • Obesity6
  • Colorectal Cancer6
  • Diabetes Mellitus, Type 26
  • Diabetes Mellitus5

Frequently asked questions about Amsterdam UMC, location VUmc

How many clinical trials does Amsterdam UMC, location VUmc have on ClinicalTrials.gov?
Amsterdam UMC, location VUmc is listed as the lead sponsor on 300 clinical trials in ClinicalTrials.gov, 67 of which are currently active (recruiting, enrolling, or ongoing).
How many of Amsterdam UMC, location VUmc's trials are in Phase 3?
18 of Amsterdam UMC, location VUmc's trials are in Phase 3, spread across 22 active drug programs.
What therapeutic areas does Amsterdam UMC, location VUmc focus on?
Amsterdam UMC, location VUmc's most-studied conditions on ClinicalTrials.gov are Multiple Sclerosis, Coronary Artery Disease, Breast Cancer, Type 2 Diabetes, Obesity.
When are Amsterdam UMC, location VUmc's next clinical trial readouts?
Amsterdam UMC, location VUmc has 10 upcoming primary-completion readouts tracked here; the soonest is “DiEtary Sodium Intake Effects on Ertugliflozin-induced Changes in GFR, reNal Oxygenation and Systemic Hemodynamics: the DESIGN Study, a Randomized, Placebo-controlled, Cross-over Study With Ertugliflozin in People With Type 2 Diabetes”, expected around 2025-12.